Pathway to Cures

Managing Director & Officer Teri Willey leads the fund day-to-day, supported by Venture Principal Tim Brent and a cross-functional group of investment professionals, scientific researchers, and medical volunteers. The team operates within NBDF's governance framework but makes independent investment decisions.

P2C leverages the National Bleeding Disorders Foundation's deep scientific and clinical network to identify early-stage assets addressing inheritable blood and bleeding disorders. By connecting with researchers, clinicians, and advocacy communities, the fund surfaces companies that are often overlooked by traditional venture capital.

No. P2C is a 501(c)(3) venture philanthropy fund, not a for-profit private equity vehicle. All donations flow into mission-aligned investments, and any financial returns are reinvested into the portfolio. Neither management nor donors receive capital distributions.

The fund explicitly seeks to attract follow-on capital from traditional VC, biotech, and pharma by de-risking early-stage science through its own due diligence and NBDF's expert network. P2C's own commitment aims to validate opportunities for subsequent private-sector rounds.

P2C invests exclusively in companies developing therapies and technologies for inheritable blood and bleeding disorders. This includes conditions such as von Willebrand disease and platelet disorders, explicitly excluding areas outside that disease scope.

NBDF is both P2C's parent organization and a donor, supplying critical scientific and advocacy resources. Operationally, P2C functions independently with its own investment team, using NBDF's relationships and expertise to inform deal selection and diligence.

P2C asks for a minimum donation of $500,000 from individuals, groups, or institutions. This threshold is designed to concentrate capital and accelerate portfolio growth across multiple inheritable blood and bleeding disorders.